Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)
Status:
Not yet recruiting
Trial end date:
2025-06-13
Target enrollment:
Participant gender:
Summary
The primary objective is to evaluate in participants with high-grade serous ovarian cancer
(HGSOC), whether the reduction from baseline in circulating tumor DNA (ctDNA) at Cycle 3
(ΔctDNA) is larger in participants receiving MK-4830 + pembrolizumab in combination with
standard of care (SOC) therapy than in those receiving pembrolizumab + SOC therapy.